Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04743141 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
A Phase 3 study of Acute Treatment of Migraine, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT04743141 is a Phase 3 study of Acute Treatment of Migraine that is actively recruiting participants, run by Pfizer. The registered enrollment target is 600 participants. The trial reports 20 study locations across 3 states.
The verdict
NCT04743141, a Phase 3 study of Acute Treatment of Migraine, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).
Conditions Studied
Interventions
- DRUG Rimegepant (PF-07899801)
Study Locations (20)
California
- Advanced Research Center, Inc. - Anaheim
- ProScience Research Group - Culver City
- Neuro-Pain Medical Center - Fresno
- Regents of the University of California (UC San Diego) - La Jolla
- Adult & Child Neurology Medical Associates - Long Beach
- Memorialcare Miller Children's & Women's Hospital Long Beach - Long Beach
- Velocity Clinical Research - North Hollywood - North Hollywood
- The Neurology Group - Pomona
- UC Davis Medical Center, Investigational Drug Service (IDS) Pharmacy - Sacramento
- University of California, Davis Clinical and Translational Science Center Clinical Research Center - Sacramento
- University of California, Davis Midtown Clinic - Sacramento
- Velocity Clinical Research- Banning - San Bernardino
- Pacific Clinical Research Management Group LLC - Upland
- Sunwise Clinical Research - Walnut Creek
Colorado
- Children's Hospital Colorado- Investigational Drug Services - Aurora
- Children's Hospital Colorado - Aurora
- Colorado Springs Neurological Associates, PC - Colorado Springs
- Colorado Springs Neurological Associates, PC - Colorado Springs
Arizona
- Perseverance Research Center, LLC - Scottsdale
- Physicians Research Group - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2021-04-28 |
| Est. Completion | 2030-07-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04743141
The ClinicalTrials.gov registry entry for NCT04743141 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Treatment of Migraine appearing as the primary indexed condition, and to 1 intervention - of which Rimegepant (PF-07899801) is the first listed.
NCT04743141 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Colorado, Arizona.
Frequently Asked Questions
What is clinical trial NCT04743141 about?
NCT04743141 is a clinical study titled "Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine". The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).
What is the current status of trial NCT04743141?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2021-04-28. Estimated completion is 2030-07-31.
What conditions does trial NCT04743141 study?
This clinical trial studies the following conditions: Acute Treatment of Migraine.
What interventions are being tested in trial NCT04743141?
The interventions under investigation include: Rimegepant (PF-07899801) (DRUG).
Who is sponsoring clinical trial NCT04743141?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04743141 being conducted?
This trial has 20 study locations across Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Treatment of Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.